B Capital

B Capital is built around a multistage, sector‑focused thesis: partner with bold entrepreneurs shaping tomorrow across Technology & AI, Healthcare and Energy & Resilience, and compound value by marrying purpose‑built operating support with BCG’s global consulting and corporate networks. In Technology & AI, the firm concentrates on enterprise software, fintech and developer/AI infrastructure—where new capabilities and novel applications are reshaping foundational industries. It backs both early category creators (pre‑seed/Series A) and scaling leaders (Series B+), often leveraging BCG’s Fortune 1000 access for distribution and strategic validation. In Healthcare, dedicated capital targets the spectrum from healthcare IT/digital health to biotechnology and bio‑IT, anchored in the belief that the convergence of biology, AI and automation is upending discovery, care delivery and payment models. In Energy & Resilience, B Capital frames opportunity through three megatrends—surging electricity demand, rising system volatility and supply‑chain derisking—and invests across the energy/industrial/infrastructure stack where speed‑to‑power, cost and real grid integration drive advantage. Geographically, the firm operates globally with an emphasis on North America and Asia, reflecting deep roots across the U.S., India/SEA and selective China exposure, and an ability to help founders expand across borders and boundaries. Stage architecture is explicit: Ascent backs pre‑seed through Series A; Growth Fund III backs global growth; Opportunities Fund II concentrates on later‑stage follow‑ons and select new/secondary opportunities in top‑performing companies. The core belief about value creation is that a founder‑aligned, platformed investor—combining sector‑operating GPs with BCG’s scale—can accelerate company building from seed to IPO, including GTM, enterprise access, capital strategy and organization building. They avoid one‑off, single‑market plays and hype without substance, preferring globally relevant, infrastructure‑led innovation with durable moats.

B Capital’s decisioning is thesis‑ and sector‑operator driven, pairing domain GPs with BCG’s advisory reach. At early stage (Ascent), they prioritize extraordinary founders with deep domain insight and global ambition, often ahead of visible market consensus. The mandate spans pre‑seed to Series A in enterprise software/AI, fintech, logistics and digital health; qualitative signals such as team quality, problem intensity, and differentiated wedges like regulatory or distribution can outweigh near‑term revenue if there is technical depth and a credible path to compounding advantage. In growth and later stages, B Capital leans into catalysts where its platform can accelerate value creation—e.g., enterprise go‑to‑market, Fortune 1000 access via BCG, capital advisory and organizational build‑out. In energy and resilience, principles emphasize speed‑to‑power, cost curves and grid transformation, favoring businesses with defensible execution in regulated markets. In healthcare, the team seeks convergence of biology, AI and automation, with attention to clinical/regulatory milestones. While no fixed ARR thresholds are published, they expect real metrics by Series B (engagement, unit economics, customer behavior) and look for scale indicators matched to sector context (MW under management in energy, validated clinical progress in biotech, durable net retention in SaaS). The firm frequently leads early and selectively leads or follows in growth when its platform and BCG partnership can be needle‑moving.

• AtomwiseLead
  AI-driven drug discovery aligns with B Capital’s Healthcare and AI thesis; B Capital co-led the $123M Series B to scale the platform.
• Phenom (Phenom People)Lead
  Enterprise AI talent experience platform; B Capital led the $100M Series D growth round to accelerate category leadership.
• YaloLead
  Conversational commerce infrastructure for WhatsApp-scale markets; B Capital led the Series C to expand in emerging markets.
• CompanyCamLead
  Vertical SaaS for contractors with AI features; B Capital led the Series C strategic growth investment.
• IcertisLead
  Category-leading CLM SaaS with strong expansion and low churn; B Capital led the Series C and later growth rounds.
• UlaLead
  B2B marketplace modernizing retail supply chains in Indonesia; B Capital co-led the Series A, fitting the firm’s Asia focus.
• Evidation HealthLead
  Digital health/real-world evidence platform; B Capital co-led the Series C, aligning with its healthcare data thesis.
• Eureka RoboticsLead
  Robotics and AI for precision manufacturing; B Capital led the $10.5M Series A, fitting deep-tech/industrial automation focus.
• AxiomLead
  Foundational math reasoning toward superintelligence; B Capital led the Seed round, matching its frontier AI thesis.

• GG
  Gabe Greenbaum

  General Partner – Americas (Early Stage, Technology/AI)

  TechnologyArtificial Intelligence
• RM
  Robert Mittendorff

  General Partner – Global Head of Healthcare

  Healthcare
• JJ
  Jeff Johnson

  General Partner – Global Head of Energy Tech

  Energy TechnologyCleanTech
• KM
  Karan Mohla

  General Partner – South & Southeast Asia

  South AsiaSoutheast AsiaEarly & Growth Stage